Pharmacokinetics of emedastine difumarate, a new anti-histaminic agent in patients with renal impairment

Author： Joukhadar Christian   Herranz Ursula   Pernerstorfer Thomas   Assandri Alessandro   Klein Nikolas   Schrolnberger Claudia   Lackner Edith   Eichler Hans G.   Müller Markus  

Publisher： Springer Publishing Company

ISSN： 0031-6970

Source： European Journal of Clinical Pharmacology, Vol.56, Iss.12, 2001-03, pp. : 905-910

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Pharmacokinetics of Metrifonate and its Metabolite Dichlorvos in Healthy Volunteers and in Patients with Renal Impairment

By Heinig R.  

Clinical Drug Investigation, Vol. 18, Iss. 1, 1999-07 ,pp. : 35-46

Adis International

Access to resources Recommend Favorite

Pharmacokinetics and Safety of Ebastine in Healthy Subjects and Patients with Renal Impairment

By Noveck Robert J.  

Clinical Pharmacokinetics, Vol. 46, Iss. 6, 2007-01 ,pp. : 525-534

Adis International

Access to resources Recommend Favorite

Asenapine Pharmacokinetics in Hepatic and Renal Impairment

By Peeters Pierre  

Clinical Pharmacokinetics, Vol. 50, Iss. 7, 2011-07 ,pp. : 471-481

Adis International

Access to resources Recommend Favorite

The pharmacokinetics (PK) of aprepitant are not affected in patients with end-stage renal disease (ESRD) or severe renal impairment

By  

Inpharma, Vol. 1, Iss. 1494, 2005-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin

By Boulton David W.   Li Li   Frevert Ernst U.   Tang Angela   Castaneda Lorna   Vachharajani Nimish N.   Kornhauser David M.   Patel Chirag G.  

Clinical Pharmacokinetics, Vol. 50, Iss. 4, 2011-04 ,pp. : 253-265

Adis International

Access to resources Recommend Favorite